Lab Results
Lipid Panel Explained: LDL Particle Size, HDL, Triglycerides, and ApoB
A standard cholesterol test tells you far less than you think. Most people are handed a lipid panel showing 'normal' LDL and sent home — yet up to half of first heart attacks occur in people with seemingly acceptable cholesterol numbers. Understanding LDL particle size, ApoB, HDL quality, and the triglyceride-to-HDL ratio transforms a routine lab printout into a genuine roadmap for cardiovascular risk reduction.
Lipid Panel Explained: LDL Particle Size, HDL, Triglycerides, and ApoB
A standard lipid panel — total cholesterol, LDL-C, HDL-C, and triglycerides — has been the cornerstone of cardiovascular screening for decades. But cardiologists and functional medicine practitioners increasingly agree: that four-number snapshot misses critical information. Accurate lipid panel interpretation requires understanding what those numbers actually measure, what they don't, and which additional markers — especially LDL particle size and apolipoprotein B (ApoB) — give a far more precise picture of arterial health.
This guide unpacks each component of an advanced lipid panel, explains how the numbers interact, and shows you how to use that data to make smarter decisions about nutrition, supplementation, and lifestyle.
---
Why Standard LDL-C Can Be Misleading
LDL cholesterol (LDL-C) measures the total amount of cholesterol carried inside LDL particles — not the number of particles doing the carrying. This distinction matters enormously. You can have the same LDL-C of 110 mg/dL with 700 large, buoyant particles or with 1,400 small, dense particles. The person with twice as many particles faces substantially higher risk because each particle is an independent vehicle that can embed in arterial walls.
The landmark MESA (Multi-Ethnic Study of Atherosclerosis) study, which followed over 6,800 participants, confirmed that LDL particle number (LDL-P) predicted cardiovascular events significantly better than LDL-C in people who would otherwise appear low-risk (Cromwell et al., Journal of the American College of Cardiology 2007; PMID: 17719466). This is sometimes called "LDL discordance" — when LDL-C and LDL-P point in different directions, LDL-P wins as the better predictor.
For a deeper look at how omega-3 EPA and DHA affect LDL particle composition, the evidence points toward meaningful shifts in particle phenotype with sustained supplementation.
---
LDL Particle Size Test: What Small Dense LDL Really Means
LDL particles exist on a spectrum from large and buoyant (Pattern A) to small and dense (Pattern B). Small dense LDL (sdLDL) is considered more atherogenic for several reasons:
- It has lower binding affinity for the LDL receptor, so it stays in circulation longer.
- It penetrates the arterial endothelium more easily due to its size.
- It is more susceptible to oxidation, and oxidized LDL is a key driver of foam cell formation and plaque development.
A 2014 meta-analysis in the European Heart Journal (including 19 prospective studies, approximately 20,000 participants) found that sdLDL was independently associated with a 36% increased risk of coronary heart disease compared with large-buoyant LDL, even after adjusting for LDL-C (Ivanova et al., European Heart Journal 2017; doi.org/10.1093/eurheartj/ehx531).
How to test it: The NMR LipoProfile (LabCorp) and the Cardio IQ Ion Mobility assay (Quest) both measure LDL particle size and number. These are not included in a standard lipid panel and must be ordered separately or through advanced testing platforms.
Reference ranges for LDL particle number (LDL-P):
| Risk Category | LDL-P (nmol/L) |
|---|---|
| Optimal | < 1,000 |
| Near optimal | 1,000 – 1,299 |
| Borderline high | 1,300 – 1,599 |
| High | ≥ 1,600 |
Dietary and lifestyle changes that reduce sdLDL include replacing refined carbohydrates with fiber-rich whole foods, increasing omega-3 fatty acid intake, and correcting insulin resistance — which is the most common upstream driver of a Pattern B profile.
---
ApoB Cardiovascular Risk: The Single Best Atherogenic Marker
Apolipoprotein B (ApoB) is a structural protein that sits on the surface of every atherogenic lipoprotein particle: VLDL, IDL, LDL, and Lp(a). Because each particle carries exactly one ApoB molecule, the ApoB blood level is essentially a direct count of all atherogenic particles in circulation — making it arguably the most clinically actionable marker on an advanced lipid panel.
The emerging consensus among preventive cardiologists is that ApoB should replace or at minimum accompany LDL-C in cardiovascular risk assessment. A landmark individual-participant meta-analysis published in The Lancet (Di Angelantonio et al., 2009; PMID: 19801900) found that ApoB was a superior predictor of vascular events compared with LDL-C or non-HDL cholesterol across 68 prospective studies involving over 300,000 participants.
More recently, the 2022 European Society of Cardiology guidelines on cardiovascular disease prevention explicitly included ApoB as a recommended risk marker, suggesting targets below 65 mg/dL for very high-risk individuals and below 80 mg/dL for high-risk individuals (Visseren et al., European Heart Journal 2021; doi.org/10.1093/eurheartj/ehab484).
Practical ApoB targets:
| Population | ApoB Target |
|---|---|
| Low cardiovascular risk | < 100 mg/dL |
| Moderate risk | < 90 mg/dL |
| High risk (existing CVD, diabetes) | < 80 mg/dL |
| Very high risk | < 65 mg/dL |
ApoB is particularly valuable when LDL-C appears normal but the patient has metabolic syndrome, elevated triglycerides, or insulin resistance — all situations where there may be a high number of sdLDL particles without a proportionally elevated LDL-C. If you are using a platform like Ones that ingests your blood work, ApoB is one of the first markers the AI flags when building a cardiovascular support strategy.
---
HDL Cholesterol Optimal Levels: Quality Matters as Much as Quantity
For years, clinicians used a simple rule: higher HDL is better. HDL-C above 60 mg/dL was considered cardioprotective. More recent research has complicated this picture substantially.
While low HDL-C (below 40 mg/dL in men, below 50 mg/dL in women) is a well-validated risk factor, very high HDL-C — particularly above 80–90 mg/dL — does not confer additional protection and in some analyses is associated with increased all-cause mortality (Madsen et al., European Heart Journal 2017; doi.org/10.1093/eurheartj/ehx163).
The reason: HDL is not a monolithic particle. Its function — specifically its ability to accept cholesterol from macrophages in arterial walls via reverse cholesterol transport — is what matters. Dysfunctional HDL can be inflammatory rather than protective, regardless of its absolute concentration.
Optimal HDL-C reference ranges:
| Sex | Low (Risk Factor) | Acceptable | Optimal |
|---|---|---|---|
| Male | < 40 mg/dL | 40–59 mg/dL | 50–70 mg/dL |
| Female | < 50 mg/dL | 50–69 mg/dL | 60–80 mg/dL |
Factors that raise HDL-C and improve HDL function include aerobic exercise, moderate alcohol elimination (paradoxically, alcohol raises HDL-C but may worsen HDL function), smoking cessation, and omega-3 fatty acid supplementation. Niacin raises HDL-C substantially but failed to reduce cardiovascular events in large trials (AIM-HIGH, HPS2-THRIVE), suggesting that HDL quantity and quality are not interchangeable.
For individuals focused on comprehensive cardiovascular support through supplementation, HDL optimization is best addressed through the lifestyle levers above combined with targeted nutrient repletion.
---
Triglyceride HDL Ratio: A Practical Insulin Resistance Proxy
The triglyceride-to-HDL ratio (TG:HDL) may be the most underutilized number you can calculate from a standard lipid panel. Divide your fasting triglycerides by your HDL-C. A ratio above 3.0 is strongly associated with insulin resistance and a Pattern B (small dense) LDL profile, even when LDL-C appears normal.
A study using data from the Tehran Lipid and Glucose Study found that a TG:HDL ratio ≥ 3.0 had a sensitivity of 64% and specificity of 68% for identifying insulin resistance as defined by HOMA-IR (Salazar et al., Cardiovascular Diabetology 2012; doi.org/10.1186/1475-2840-11-103).
In clinical practice, many functional medicine cardiologists consider TG:HDL the most accessible surrogate marker for atherogenic dyslipidemia — the dangerous lipid pattern that develops with metabolic syndrome, where LDL-C is deceivingly normal but particle number is high, HDL is low, and triglycerides are elevated.
TG:HDL ratio interpretation:
| TG:HDL Ratio | Interpretation |
|---|---|
| < 1.5 | Optimal — likely Pattern A (large, buoyant LDL) |
| 1.5 – 3.0 | Acceptable — mixed picture |
| 3.0 – 5.0 | Elevated — probable insulin resistance, Pattern B |
| > 5.0 | High concern — metabolic dyslipidemia, further testing warranted |
Reducing the TG:HDL ratio requires addressing its root causes: reducing dietary refined carbohydrates and added sugars, improving insulin sensitivity through exercise and sleep, and considering targeted supplementation with omega-3 fatty acids. High-dose EPA/DHA (2–4 g/day) is one of the most evidence-backed interventions for reducing fasting triglycerides; the REDUCE-IT trial demonstrated a 25% reduction in major cardiovascular events with 4 g/day of icosapentaenoic acid (EPA) in high-risk patients (Bhatt et al., New England Journal of Medicine 2019; PMID: 30415628).
Understanding the triglyceride HDL ratio alongside ApoB gives a much fuller picture of cardiometabolic risk than any single number alone.
---
Lp(a): The Inherited Wildcard
Lipoprotein(a) — Lp(a) — is a modified LDL particle with an additional apolipoprotein(a) protein attached. Unlike most lipid markers, Lp(a) is approximately 90% genetically determined and is not meaningfully altered by diet or most current medications. Elevated Lp(a) (generally defined as > 50 mg/dL or > 125 nmol/L) independently increases cardiovascular risk and may partially explain why some individuals develop heart disease despite otherwise optimal lipid profiles.
The 2022 ESC guidelines now recommend measuring Lp(a) at least once in every adult's lifetime. Currently, RNA-targeted therapies (pelacarsen, olpasiran) in late-stage trials show promise for Lp(a) reduction, but no approved pharmacological intervention specifically targets it. Knowing your Lp(a) level informs how aggressively other modifiable risk factors should be managed.
---
How Ones Addresses Lipid Optimization
When you upload your lipid panel — including ApoB, LDL-P, and Lp(a) if available — Ones' AI health practitioner maps the full pattern of your cardiovascular risk markers, not just isolated numbers. Based on your specific results, health history, and goals, it may include the following clinically dosed ingredients in your custom capsule formula:
Omega-3 (EPA/DHA): Ones sources pharmaceutical-grade EPA and DHA dosed to clinically relevant levels for triglyceride reduction and anti-inflammatory benefit. The REDUCE-IT trial confirmed the cardiovascular benefit of high-dose EPA, and Ones calibrates dosing to your triglyceride levels and capsule budget. If you're exploring how EPA and DHA ratios affect cardiovascular outcomes, the evidence clearly supports meaningful supplementation when dietary intake is insufficient.
CoQ10/Ubiquinol (200 mg): Mitochondrial function and oxidative stress are upstream drivers of LDL oxidation and endothelial dysfunction. Ones includes CoQ10 as ubiquinol — the active, reduced form — at 200 mg, matching the dose used in studies of cardiovascular function. Ubiquinol is particularly relevant for individuals on statins, which deplete endogenous CoQ10 (Mortensen et al., JACC Heart Failure 2014; PMID: 24944033).
Heart Support System Blend: For users with elevated cardiovascular risk markers, Ones' proprietary Heart Support blend combines validated botanicals and micronutrients — including berberine, tocotrienols, and targeted B vitamins — chosen to support healthy lipid metabolism and endothelial function at doses aligned with available clinical evidence.
Because Ones formulas come in 6, 9, or 12-capsule plans, cardiovascular ingredients are prioritized and weighted against your full supplement budget — ensuring the most impactful ingredients for your specific lipid pattern make the cut.
---
Key Takeaways
- LDL-C alone is insufficient for cardiovascular risk assessment; LDL particle number and size are stronger predictors of atherogenic risk, especially when LDL-C and LDL-P are discordant.
- ApoB is the gold standard atherogenic particle count — one number that captures LDL, VLDL, IDL, and Lp(a) risk simultaneously; target below 80 mg/dL for high-risk individuals per ESC 2022 guidelines.
- HDL quality matters more than quantity — very high HDL-C does not guarantee protection; improving HDL function through exercise, smoking cessation, and omega-3s is more impactful than chasing the number.
- The TG:HDL ratio (target < 1.5) is a practical, free-to-calculate proxy for insulin resistance and small dense LDL burden that is often more informative than LDL-C in metabolic syndrome.
- Lp(a) should be tested at least once in every adult — it is largely genetic, not diet-responsive, and when elevated requires more aggressive management of all other modifiable cardiovascular risk factors.
- Targeted supplementation — particularly high-dose omega-3s, ubiquinol CoQ10, and berberine-containing formulas — has clinical evidence supporting improvements in triglycerides, LDL oxidation, and endothelial function, especially when personalized to your actual lab results.
Always consult a qualified healthcare provider before making changes to your supplement regimen or interpreting lab results for medical decisions.